Mutations in BRAF and KRAS, acting in the RAS-RAF-MAPK kinase cascade and mutated PIK3CA, acting in PI3K-PTEN-AKT signaling pathway, are known for their contribution to the development of CRC and are associated with cancer prognosis [11, 33]. The gene discussed is KRAS; the disease is cancer.